-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Selpercatinib is a first-line highly selective RET kinase inhibitor with CNS activity that has shown efficacy
The LIBRETTO-001 study was designed to assess the efficacy and safety
The study was an ongoing 1/2, single-group, open-label basket trial of cancer patients aged 18 years (or ≥ 12 years, with regulatory authority permission) who had progressed after previous treatment with RET variants or did not have satisfactory treatment options, and administered Selpercatinib orally, and in the phase 1 dose increment, patients received Selpercatinib 20 mg/day or 20-240 mg*2 times/day; The recommended dose for Phase 2 is 160 mg*2 times/day
Between December 4, 2017 and August 4, 2021, a total of 45 RET fusion-positive cancer patients
Among the 41 patients whose efficacy could be evaluated, the objective response rate was 43.
In summary, Selpercatinib showed clinically significant activity in patients with RET fusion-positive tumors, and its safety was consistent
Original Source:
Vivek Subbiah, et al.